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ABSTRACT 
 
Skeletal muscle of obese Zucker rats function at higher rates of anabolism when 
compared to lean littermates, and are resistant to the anabolic effect of exercise.  We 
recently determined that DEP domain containing mammalian target of rapamycin 
(mTOR)-interacting protein (DEPTOR), a potent negative binding partner of mTOR, is 
reduced in skeletal muscle of diabetic rats, suggesting that regulation of this protein may 
participate in the altered protein metabolism.  The purpose of this investigation was to 
assess key regulators of DEPTOR expression, RING-box protein 1 (Rbx1) and beta-
transducin repeat-containing protein (β-TrCP), in gastrocnemius muscle of rats with or 
without type 2 diabetes, with or without in vivo resistance exercise.  We hypothesized 
that the reduced expression of DEPTOR would be accompanied by altered expression of 
Rbx1 and/or β-TrCP.  Tissues from thirty male Zucker rats (16 lean [L], 14 obese [F]) 
collected from previous studies were used for this investigation.  Rats were subsequently 
assigned to sedentary ([S]; 8 LS, 6 FS) or resistance exercise ([E]; 8 LE, 8 FE) groups.  
Exercised rats participated in four progressive bouts, with increasing repetitions and 
loads, over 8 days.   
Results indicate that DEPTOR mRNA levels were consistent with previously 
reported protein levels, with reduced content in LE compared to LS (p<0.05) and obese 
groups (FS and FE) not different than LE (p>0.05).  β-TrCP protein levels were not 
affected by exercise, but were higher (39%) in obese compared to lean animals; whereas, 
β-TrCP mRNA content was 113% greater in FE compared to FS (p<0.05).  There was a 
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main effect of resistance exercise on Rbx1 protein content, where exercised animals had 
30% lower levels of protein than sedentary animals.  Further analysis revealed that Rbx1 
protein content was suppressed by exercise in lean animals only (49% lower).  A main 
effect of exercise was also observed for Rbx1 mRNA, where exercised animals 
displayed 47% higher levels than sedentary animals (p<0.05).   
In conclusion, we speculate that the heightened anabolic function in obese 
animals may be partly due to increased protein levels of β-TrCP, which may lead to 
suppressed DEPTOR levels and unrestricted mTOR activity.  Additionally, the β-TrCP 
/DEPTOR interaction may be a key culprit for the reported resistance to anabolic stimuli 
in diabetic skeletal muscle. 
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NOMENCLATURE 
 
BW Body weight 
β-TrCP Beta-transducin repeat-containing protein 
DEPTOR DEP domain containing mTOR-interacting protein 
DNA Deoxyribonucleic acid 
mRNA Messenger ribonucleic acid 
mTOR Mammalian target of rapamycin 
PCR Polymerase chain reaction 
Rbx1 RING-box protein 1 
RNA Ribonucleic acid 
SCF Skp1-Cullin1-F-box protein 
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INTRODUCTION AND LITERATURE REVIEW 
  
Diabetes - a global epidemic.  Type 2 diabetes is one of the most common 
chronic diseases around the world, and its prevalence continues to escalate due to a 
general shift in lifestyle toward the consumption of higher calorie diets, reduced physical 
activity, and increased obesity (66).  In addition to insulin resistance and hyperglycemia, 
type 2 diabetes is a metabolic disease also characterized by hyperinsulinemia, 
dyslipidemia, and altered protein metabolism, a cluster of abnormalities often referred to 
as the metabolic syndrome.  As the risk of diabetes tends to increase with increasing 
body mass index (BMI), it is of great concern that, in the US alone, nearly 70% of adults 
are overweight or obese (BMI≥25.0) (21).  As such, the Centers for Disease Control 
(CDC) reported that 25.8 million (or 8.3% of) Americans were afflicted with diabetes in 
2011, and if current trends continue, it is projected that 30% of US adults could have 
diabetes by the year 2050 (1).  At present in in the US, diabetes is the 7
th
 leading cause 
of death, the leading cause of kidney failure, non-traumatic lower limb amputations, and 
new cases of blindness, and is a major cause of heart disease and stroke, the number one 
and four leading causes of death, respectively, among American adults (1).  In fact, the 
risk of death among people with diabetes is roughly twice that of individuals with 
similar characteristics, but without diabetes.  Thus, development of treatments or 
preventative therapies is of paramount importance for maintaining not only the health of 
individuals with diabetes, but also for reducing the ever-increasing burden on the health 
care industry. 
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Etiology of type 2 diabetes.  Due to the seemingly unlimited number of factors 
that underlie the diseased state, understanding factors leading to insulin resistance and 
type 2 diabetes has proven problematic.  Historically, the focus in diabetes research has 
been on hyperglycemia, the main clinical manifestation, with disease progression 
believed to begin with a loss of insulin sensitivity in peripheral (adipose and skeletal 
muscle) and liver tissues, followed by increased insulin secretion by pancreatic β-cells to 
maintain glucose homeostasis until, eventually, the β-cells can no longer generate 
enough insulin to meet tissue demands to overcome insulin resistance (13).  In addition 
to the waning ability of skeletal muscle and adipose tissue to take up glucose from the 
bloodstream, type 2 diabetes is also characterized by increased hepatic glucose 
production (HGP) in the post-absorptive state (12- to 16-hour overnight fast) along with 
a dampened ability of insulin to subdue HGP (insulin resistance) (20).  The normal, 
healthy response to increased gluconeogenesis is compensation by decreasing 
glycogenolysis, due to hyperinsulinemia, thereby maintaining hepatic glucose output 
(referred to as hepatic autoregulation) (39).  However, with type 2 diabetes it is thought 
that a breakdown of this hepatic autoregulation is a main contributor to the increased 
HGP and output.  Furthermore, the elevated HGP observed in type 2 diabetes has been 
attributed to elevated circulating plasma free fatty acids (FFA) (46), hyperglucagonemia 
(3), increased levels of precursors to gluconeogenesis, such as lactate, alanine, and 
glycerol (9, 10), heightened sensitivity to glucagon (49), and reduced sensitivity to 
insulin (9). 
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It is well established that skeletal muscle is the primary site of insulin-stimulated 
glucose uptake, accounting for about 90% of whole-body glucose metabolism (67), thus 
making muscle an important player in the pathogenesis of insulin resistance.  Glucose 
enters skeletal muscle cells by facilitated diffusion through glucose transporter protein 
isoform 1 (GLUT1) and GLUT4.  While GLUT1 resides in the plasma membrane and is 
thought to mediate basal glucose transport, GLUT4 increases glucose uptake in muscle 
as the protein translocates from its intracellular storage compartment to the membrane in 
response to insulin or muscle contraction stimuli (32). 
As GLUT4 has an essential role in insulin-mediated glucose transport, and type 2 
diabetes is often recognized by elevated plasma glucose levels, it is not surprising that 
numerous research studies have been carried out to examine the effects of altered 
GLUT4 expression with diabetes.  In transgenic mice exhibiting overexpression of 
human GLUT4 there has been an observed augmentation of skeletal muscle glucose 
transport, short-term, in the presence of insulin and muscle contraction (6, 32).  
Conversely, genetic disruption of GLUT4 in skeletal muscle has reportedly induced 
insulin resistance and glucose intolerance in mice (81).  Although defects in GLUT4 
expression have not been proven to cause the insulin resistance associated with type 2 
diabetes, genetic overexpression or contraction-induced elevation of GLUT4 expression 
do appear to improve insulin sensitivity in rodents and humans with diabetes (6, 32, 81). 
Type 2 diabetes is not due to ‘broken’ glucose regulation.  Recent insight has 
provided exciting new possibilities that type 2 diabetes is not due to a breakdown of 
glucose regulation, but perhaps to some other underlying feature of metabolism which 
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leads to a compensatory shift in glucose metabolism.  Mitochondria are critical 
organelles for energy production for nearly all cellular processes, and their ability to 
switch between oxidation of glucose and fat requires their proper functioning.  David 
Kelley and colleagues (43, 61, 62) have demonstrated that one such factor in glucose 
dysregulation is due to altered mitochondrial function.  They reported that subjects with 
type 2 diabetes and obesity have smaller and less efficient (i.e., diminished bioenergetic 
capacity) skeletal muscle mitochondria compared to lean subjects (43).  Since then, a 
plethora of studies has emerged indicating that altered glucose regulation features a 
complex interaction between cellular processes in metabolism leading to a directed 
reduction of glucose uptake in the cell.  Those types of studies have led to an altered 
perception regarding the etiology of the disease, and while the cure remains distant, 
addressing other aspects of the cell leading to this glucoregulatory disorder appears 
promising. 
It has been purported that insulin resistance in diabetic skeletal muscle is due to 
an elevated rate of lipid oxidation that is unable to match an excessive FFA uptake, 
leading to accumulation of intramyocellular lipid metabolites associated with 
triacylglycerol, including diacylglycerol (DAG), long-chain fatty acyl-CoA, and/or 
ceramide (11, 37, 65, 70).  Those compounds may affect muscle and whole-body 
glucose (and protein) metabolism by interfering with insulin signaling through activation 
of serine/threonine kinases.  Itani et al. (2000) conducted a study to investigate protein 
kinase C (PKC) involvement with excessive serine/threonine phosphorylation of the 
insulin receptor in skeletal muscle of insulin resistant patients (38).  Results of that study 
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indicated that insulin receptor tyrosine kinase activity was reduced as a result of 
hyperphosphorylation on serine/threonine residues, along with an increased PKC activity 
in insulin-resistant skeletal muscle, leading to the postulation that the decline in tyrosine 
kinase activity of the insulin receptor may be caused by serine/threonine phosphorylation 
by PKC (38).   
Altered protein metabolism in type 2 diabetes.  Insulin-mediated glucose uptake 
and protein anabolism are implicated in the same signaling pathway, and considering 
type 2 diabetes is accompanied by faulty glucose metabolism, it is fitting that alterations 
in anabolic processes are also observed with the diseased state.  To expand on that 
notion, Fluckey et al. (22) demonstrated that insulin-mediated alterations of PKC activity 
in diabetic muscle may not only disrupt glucose metabolism, but may also play a role in 
augmented anabolic responses to insulin, in situ.  Of particular interest is that inhibition 
of PKC using a pharmacological inhibitor not only reduced PKC activation following 
insulin stimulation, but also normalized protein metabolism (22).  Further, using a 
pharmacological agonist that is known for disruption of glucose metabolism (12), insulin 
responses to anabolism in normal muscle were augmented (22), suggesting that 
alterations of upstream signals in the signal transduction pathway differentially affect 
downstream metabolic pathways.  Those studies demonstrated a direct link between 
glucoregulatory and anabolic pathways that respond in an inverse manner (i.e., the 
insulin signal leads to upregulation of one pathway while downregulating another).   
Treating type 2 diabetes and insulin resistance.  Strategies for the treatment of 
type 2 diabetes have almost exclusively been (and largely, still are) focused on reversing 
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hyperglycemia by stimulating glucose uptake, even in the face of insulin resistance.  
Such therapies have had limited success, but have proven generally only successful for 
managing diabetic symptoms, rather than curing the disease itself.  There have been 
many strategies related to the treatment of individuals with type 2 diabetes and insulin 
resistance, from relatively non-invasive pharmacological approaches (14, 45) to highly 
invasive bariatric surgeries (2, 59).  Those methods seem to have limited, but effective 
outcomes on the treatment of the disease.  Other approaches have been to manage 
nutrient intake, as reductions of dietary sugar appear to assist patients with diabetes in 
maintaining manageable glycemia (5, 55).  Another relatively non-invasive approach to 
the disease is physical exercise, which appears to have a profound, albeit temporary, 
impact on insulin sensitivity (reviewed by Goldbidi et al. [30]).  In fact, both endurance 
and resistance exercise training have been shown to have transient effects on glucose 
tolerance for up to 48 hours post exercise.   
Exercise as a treatment for type 2 diabetes.  Endurance exercise has long been 
known to augment insulin action in skeletal muscle of healthy individuals, and several 
studies have demonstrated improved insulin sensitivity as a result of aerobic training in a 
variety of subjects, ranging from youth to elderly and healthy to those with type 2 
diabetes.  In fact, a single bout of aerobic exercise has been shown to stimulate glucose 
uptake in insulin resistant skeletal muscle that persists for at least 24 hours following 
exercise (33).  Additionally, Manders et al. (48) demonstrated that a single bout of 
endurance exercise can stabilize the plasma glucose response for the following 24 hours, 
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reducing the appearance of post-meal hyperglycemic spikes that are significant 
precursors in the progression of diabetic complications.   
Resistance exercise has also been effective for enhancing insulin sensitivity (17, 
23).  However, it should be noted that the hallmark of resistance exercise training is to 
facilitate adaptations in skeletal muscle leading to growth.  Thus, the use of this 
important anabolic stimulant may assist with the sarcopenia observed in type 2 diabetics 
(63).  Recently, other studies have emerged indicating that alterations of anabolic 
features of skeletal muscle may also play a role in glucoregulatory function.  Holten and 
colleagues (36) reported increased glucose clearance in trained legs of patients with type 
2 diabetes following a single leg strength-training program consisting of three 30 minute 
sessions per week for 6 weeks.  Additionally, resistance training increased GLUT4 
protein content and activities of insulin receptor, protein kinase B (Akt) α/β, and total 
glycogen synthase (36).  However, these alterations seemed to be independent of gains 
in muscle mass, as only the healthy subjects (without type 2 diabetes) exhibited skeletal 
muscle hypertrophy.  There is also evidence suggestive that the phosphorylation 
(activation) of the mitogen activated protein kinase (MAPK), believed to play a critical 
role in mediating cellular events following contractile activity, is altered in diabetic 
skeletal muscle (41).  Consistent with those findings, our group has also reported 
abnormal protein turnover and a diminished response to resistance exercise-induced 
anabolic processes in rats with diabetes (52, 53).  Those studies have disclosed a direct 
link for altered signaling of protein metabolism and insulin resistance to glucose uptake. 
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 mTOR complex composition and action.  The mammalian target of rapamycin 
(mTOR), an evolutionary conserved serine/threonine kinase, is a member of the 
phosphoinositide-3 kinase (PI3K)-related protein kinase family and is of fundamental 
importance to the regulation of numerous cellular processes, including cell growth, 
apoptosis, and metabolism (64).  mTOR exists in two structurally and functionally 
distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) 
(64).  mTORC1 is made up of mTOR, regulatory associated protein of mTOR (raptor), 
proline-rich Akt substrate 40 kDa (PRAS40), DEP domain containing mTOR-interacting 
protein (DEPTOR), and mammalian lethal with sec-13 protein 8 (mLST8, also known as 
GβL) (47).  mTORC2 consists of mTOR, DEPTOR, mLST8, rapamycin-insensitive 
companion of mTOR (rictor), mammalian stress-activated MAPK-interacting protein 1 
(mSin1), and protein observed with rictor 1 and 2 (protor1/2) (47).  In response to amino 
acids, stress, oxygen, energy and growth factor stimuli (for example, insulin and insulin-
like growth factor [IGF]), mTORC1 promotes cellular growth by phosphorylating 
ribosomal protein S6 kinase 1 (p70-S6K1 or S6K1), eukaryotic translation initiation 
factor 4E-binding protein 1 (4E-BP1), and sterol regulatory element-binding protein 
(SREBP) to induce protein synthesis, lipogenesis, and energy metabolism, and inhibits 
autophagy and lysosome formation by phosphorylating autophagosome initiators 
autophagy-related protein 13 (ATG13) and UNC-51-like kinase-1 (ULK1) (47).  
mTORC2, thought to be activated by growth factors, regulates cytoskeleton organization 
and cell metabolism and survival through phosphorylation of PKC and Akt/protein 
kinase B and serum- and glucocorticoid-regulated kinase (SGK), respectively (47).   
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 Regulatory role of mTOR in metabolism.  The normal physiological response to 
elevated nutrients (amino acids and glucose) and insulin in the bloodstream following 
meal consumption is activation of mTOR to promote anabolism as well as storage and 
consumption of energy.  Specifically, mTORC1 induces mRNA translation, increases in 
cell mass, and lipid synthesis in white adipose tissue, while inhibiting autophagy, and 
mTORC2 promotes glucose uptake in most cells and glycogen synthesis in muscle and 
liver, while inhibiting gluconeogenesis in the liver (47).  Conversely, fasting causes 
declines in blood amino acid, glucose, and insulin levels which leads to decreased 
activation of mTORC1.  This downregulation of mTOR suppresses translation, liver 
glycogen synthesis, and lipogenesis and adipogenesis in adipose tissue, while 
stimulating autophagy, gluconeogenesis, lipolysis, and proteolysis to maintain cellular 
energy levels (47).  Additionally, inhibiting the action of mTORC1 results in S6K1 
inhibition, preventing uncoupling of insulin receptor substrate 1 (IRS1) from the insulin 
receptor, perhaps improving insulin sensitivity.  Considering mTOR regulatory activity 
is fundamental to so many cellular processes, it is not surprising that deregulation of the 
mTOR pathway has been implicated in many human diseases, including cancer and 
diabetes (4).   
Obesity and sarcopenia with type 2 diabetes.  Obesity often occurs as a result of 
excessive nutrient intake combined with low levels of physical activity, and the presence 
of any or all of the above is considered a major risk factor for the development of type 2 
diabetes.  A surplus of nutrients can disrupt energetic homeostasis by inducing chronic 
activation of mTORC1, which can contribute to obesity by facilitating excessive 
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deposits of ectopic fat and in turn promote insulin resistance (82).  In skeletal muscle of 
obese and high-fat-fed rodents, elevated mTORC1 activation was shown to stimulate 
S6K1-mediated negative feedback on IRS1, impairing insulin signaling and instigating 
systemic insulin resistance (44, 71).  As a result, Akt activation was blunted, glucose 
clearance and glycogen synthesis were diminished, and liver gluconeogenesis and 
release of glucose into the bloodstream were increased, thereby exacerbating the existing 
hyperglycemia and hyperinsulinemia. 
Individuals with type 2 diabetes have smaller muscles than one would predict 
based on overall mass.  This condition, known as sarcopenic obesity (63), is problematic 
because smaller muscles not only lead to reduced storage capacity for glucose disposal, 
but also to decrements in skeletal muscle function and strength.  Our group recently 
reported diminished skeletal muscle mass in obese Zucker rats, even following 
resistance exercise, that was not due to declines in muscle protein synthesis (53).  As a 
follow-up, we analyzed protein members of the mTOR signaling pathway as possible 
candidates for the reduced anabolic response (52).  Differences were not observed 
between obese and lean animals for upstream mTOR signals; however, protein levels of 
DEPTOR, an endogenous inhibitor of mTOR and associated with numerous cancers (58, 
74), were significantly reduced in obese versus lean rats, making ours the first group to 
implicate DEPTOR expression as a potential regulator of the anabolic response to 
exercise in skeletal muscle (52).  Since the observed upregulation of mTOR may be due 
to the degradation of DEPTOR, understanding the mechanisms for this protein’s 
breakdown is of critical importance.   
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DEPTOR regulation and the ubiquitin proteasome system.  The ubiquitin 
proteasome system (UPS) is critical to numerous cellular processes, from cellular growth 
to apoptosis, as it regulates a breadth of regulatory proteins via ubiquitin-mediated 
degradation by the 26S proteasome (35).  The UPS is known to involve three key 
enzymes critical to its proper functioning: an ubiquitin-activating E1 enzyme, an 
ubiquitin-conjugating E2 enzyme, and an E3 ubiquitin ligase (51).  Of these enzymes, 
the E3 ligase is the one that provides substrate specificity for ubiquitination and 
subsequent degradation of target proteins (51).   
RING ligases are one of two major classes of ubiquitin E3 ligases (HECT 
domain E3s are the other major class, see [50] for review), and facilitate the direct 
transfer of ubiquitin from an E2-bound ubiquitin to the targeted substrate.  One of the 
largest and most studied subclasses of RING E3 ligases is the cullin-RING ligases 
(CRLs), of which the SCF (Skp1-Cullin1-F-box protein) E3 is a member.  The SCF 
complex (Figure 1) is made up of four subunits: three are static, S-phase kinase-
associated protein-1 (Skp1), cullin 1 (CUL1), and RING box protein 1 (Rbx1, also 
known as regulator of cullins 1 [Roc1]), and one is variable, referred to as the F-box 
protein (26).  The CUL1 subunit acts as a molecular scaffold that interacts with Skp1, 
the adaptor subunit, at the amino terminus and with Rbx1 and an E2 enzyme at the 
carboxyl terminus (8).  Skp1 also binds to an F-box protein, of interest in this study is 
beta-transducin repeat-containing protein (β-TrCP), which in turn recognizes the target 
substrate (in this study, DEPTOR) (8).  The F-box protein binds the substrate and 
presents it in close proximity to the E2 enzyme to ensure transfer of ubiquitin to the 
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targeted protein (26, 73).  Multiple rounds of ubiquitination ensue, and then the 
polyubiquitinated substrate is targeted for proteasomal degradation. 
 
 
 
Figure 1.  SCF complex targeting DEPTOR for degradation by the 26S proteasome.  Ub, 
ubiquitin; P indicates phosphorylation; E2, Ub-conjugating enzyme.  See text for definitions.  
Adapted with permission from Wang et al. (73). 
 
 
Rbx1/Roc1 is the catalytic ring component of SCF E3 ligase.  Rbx1 is an 
ubiquitin ligase whose overexpression has been observed in lung, breast, bladder, and 
colon cancers (40, 72), and has recently been reported to be strongly associated with 
tumor progression and poor prognosis (72).  Of the SCF complex, Rbx1 and CUL1 
compose the catalytic core complex which is responsible for recruitment of the E2 
enzyme (Figure 1) (60).  SCF-type E3 ligase activity is enhanced by post-translational 
modification of CUL1 by NEDD8 (56), a protein analogous to ubiquitin, and that 
interaction is precursory to ubiquitination of substrates by SCF.  In brief, the RING 
domain of Rbx1 exhibits conformational flexibility and rotation which has a critical role 
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for controlling NEDDylation (analogous to ubiquitination, but with specific E1 [NEDD-
activating enzyme {NAE}], E2 [UBC12], and E3 [not characterized] enzymes) of CUL1 
as a signal to turn on CRL ubiquitin ligase activity (7).  Developed as a potential cancer 
therapeutic agent, MLN4924 is a newly discovered small-molecule inhibitor of NAE 
(69) that hinders the Rbx1-CUL1 interaction required for NEDDylation (activation) of 
the SCF E3 complex, and thus prevents the ubiquitin transfer from E2 to target substrate 
and (what would be) subsequent degradation (79).  Of note, Zhao and Sun (79) recently 
reported an accumulation of DEPTOR following administration of MLN4924 to various 
cancer cell lines.  Those observations support the notion that Rbx1 has an integral role in 
facilitating SCF
β-TrCP
 ubiquitin ligase activity, and suggest that Rbx1 may serve as a 
potential negative regulator of DEPTOR.   
β-TrCP is the substrate recognition subunit of the SCF E3 ligase complex.  β-
TrCP is a member of the F-box family of proteins and serves as the substrate recognition 
subunit of the SCF E3 complex (Figure 1) (73).  Recently, Zhao et al. (80) identified 
DEPTOR as a substrate of the SCF
β-TrCP
 ubiquitin ligase.  Also implicated in many 
cancers, though as both oncogene and tumor suppressor (26, 51), β-TrCP has been found 
to influence mTOR signaling by promoting the ubiquitination and destruction of 
DEPTOR (74).  Gao et al. (28) noted increased expression of DEPTOR and subsequent 
suppression of mTOR kinase activities in response to β-TrCP depletion.  However, these 
increases in DEPTOR protein levels were not accompanied by increased DEPTOR 
mRNA levels, suggesting that the accumulation of DEPTOR as a result of β-TrCP 
depletion occurs through a post-transcriptional mechanism (28).   
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The mTOR-dependent phosphorylation-driven pathway has recently been shown 
to be vital for the destruction of DEPTOR via SCF
β-TrCP 
(15, 28, 80).  Duan et al. (15), 
Gao et al. (28), and Zhao et al. (80) conducted experiments that confirmed β-TrCP 
induction of DEPTOR degradation, and that DEPTOR must be phosphorylated within its 
degron to recruit β-TrCP.  Furthermore, a prerequisite mTOR-induced ‘priming’ 
phosphorylation of DEPTOR at a non-degron site, followed by degron phosphorylation 
by casein kinase 1 (CK1α) was found to be necessary for subsequent β-TrCP recruitment 
(15, 28), supporting the suggestions that mTOR upregulates its own activity by inducing 
the degradation of its chief endogenous inhibitor. 
 Our group has recently demonstrated that DEPTOR regulation is altered in obese 
male rats exhibiting metabolic syndrome (52).  To expand on this work, the present 
investigation was performed to assess key regulators of DEPTOR expression in skeletal 
muscle of rats with or without diabetes, with or without an in vivo resistance exercise 
protocol that has been proven (25) to induce anabolism in skeletal muscle.  The 
DEPTOR regulatory proteins chosen for examination in this study were β-TrCP and 
Rbx1, given each ones integral role in DEPTOR recognition (β-TrCP) and ubiquitin 
transfer to DEPTOR (Rbx1), thus making them critical to targeting DEPTOR for 
degradation.  The central hypothesis was that changes of DEPTOR expression in skeletal 
muscle would be accompanied by altered expression of Rbx1 and/or β-TrCP.  
Specifically, in obese rats, we expected that reduced DEPTOR protein content would be 
accompanied by increased β-TrCP and/or Rbx1.  Also, given that resistance exercise 
stimulates protein synthesis in lean rats (25, 52, 53), we expected that the decline in 
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DEPTOR protein levels following exercise would be accompanied by elevated Rbx1 and 
β-TrCP expression.  
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MATERIALS AND METHODS 
 
Animals.  Tissues used in the present study were obtained from previous studies 
conducted by our lab group (31, 52, 53).  All experimental procedures were approved by 
the Institutional Animal Care and Use Committee of Texas A&M University.  Obese 
Zucker rats were chosen for use because they are an ideal animal model for 
understanding the effects of insulin resistance.  These animals carry a missense mutation 
in the leptin receptor gene and manifest symptoms similar to those of patients with type 
2 diabetes and metabolic syndrome, including hyperphagia, hyperinsulinemia (see Table 
1), hyperleptinemia, hypertriglyceridemia, hypercholesterolemia, glucose intolerance, 
insulin resistance, angiopathy, and neuropathy (54).   
Briefly, thirty 4-month-old lean (Fa/Fa or Fa/fa) and obese/fatty (fa/fa) male 
Zucker rats (Charles River Laboratories, Wilmington, MA) had free access to food 
(standard commercial rat chow, Harlan 2016 Teklad Global, Harlan Laboratories, 
Indianapolis, IN) and water while they were individually housed in a climate-controlled 
environment with a 12:12-hour light-dark cycle for the duration of the study.  Animals 
were allowed one week for acclimation then were weighed and underwent dual-energy 
x-ray absorptiometry (DXA; GE Lunar Prodigy DXA [small animal software], Madison, 
WI) scanning for body composition analysis, specifically total body mass, lean body 
mass, fat mass, and bone mass (Table 1).  To perform the scans, rats were anesthetized 
using an intraperitoneal (IP) injection of ketamine hydrochloride (Ketaset; 37.5 mg/kg 
BW) and medetomidine (Domitor; 0.25 mg/kg BW) cocktail, and then were awakened 
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by administration of antisedan immediately following the scan.  Animals were matched 
according to body composition within each phenotype (fatty or lean) then assigned to 
groups that either would or would not undergo resistance exercise.  Specifically, rats 
were in one of four groups: fatty sedentary (FS; n=6), lean sedentary (LS; n=8), fatty 
exercised (FE; n=8), or lean exercised (LE; n=8).  A significant main effect, determined 
by two-way analysis of variance (2x2 ANOVA), was observed for all DXA-derived 
variables (Table 1).  Relative to the lean phenotype, obese rats showed elevated values 
for bone mass and percent fat mass and lower values for lean mass (all p-values<0.001), 
as expected.  There were no detectable differences between experimental conditions 
within phenotypes.   
 
 
 FS, n=6 FE, n=8 LS, n=8 LE, n=8 Phenotype 
DXA      
  Body mass, g 618 ± 24
a
 586 ± 20
a
 384 ± 9.0
b
 383 ± 6.0
b
 p < 0.001 
  Bone mass, g 18.0 ± 0.7
a
 17.0 ± 0.4
a
 11.0 ± 0.2
b
 11.0 ± 0.1
b
 p < 0.001 
  Lean mass, g 222 ± 7.0
a
 229 ± 13
a
 313 ± 7.0
b
 313 ± 5.0
b
 p < 0.001 
  Fat mass, g 376 ± 18
a
 340 ± 8.0
b
 61.0 ± 6.0
c
 60.0 ± 2.0
c
 p < 0.001 
  Fat mass, % 63.0 ± 1.0
a
 60.0 ± 1.0
a
 16.0 ± 1.0
b
 16.0 ± 1.0
b
 p < 0.001 
Gastrocnemius      
  Wet mass, g 1.47 ± 0.07
a
 1.41 ± 0.04
a
 1.83 ± 0.01
b
 1.79 ± 0.05
b
 p < 0.001  
Blood      
  Insulin, µU/ml 110 ± 24
a
 126 ± 18
a
 20 ± 5
b
 17 ± 5
b
 p < 0.001 
  Glucose, mg/dl 159 ± 18
a
 150 ± 19
a
 121 ± 11
a
 129 ± 8
a
 p = 0.248 
Table 1.  Baseline body composition, endpoint muscle mass, and blood insulin and glucose 
levels.  Lean and obese Zucker rats (n=30) were matched based on lean body mass within each 
phenotype then grouped into cohorts with conditions of either sedentary or resistance exercise.  
A significant main effect of phenotype was observed for all DXA variables.  Wet mass of 
gastrocnemius muscle and fasted plasma insulin and glucose concentrations were obtained on the 
final experimental day.  Group means that are significantly different according to SNK post hoc 
analyses or t-tests do not share the same letter (p≤0.05).  FS, fatty sedentary; FE, fatty resistance 
exercised; LS, lean sedentary; LE, lean resistance exercised; DXA, dual-energy x-ray 
absorptiometry.  Values are group mean ± standard error of the mean (SEM).  Data obtained 
with permission from Nilsson et al. (53). 
 18 
 
Resistance exercise protocol.  Animals assigned to exercise groups (FE and LE) 
participated in a previously described (24) and well documented (19, 29, 34, 53, 76) 
resistance exercise protocol to elevate rates of skeletal muscle protein synthesis.  In 
brief, following acclimation, rats underwent six operant conditioning (OC) sessions over 
a two week period in which they were trained in a dark room to press an illuminated 
lever in a custom Plexiglas
®
 exercise box.  An electric foot shock (<3 mA, 60 Hz, 1-5 V) 
was employed as negative reinforcement to teach the animals to perform what resembles 
a traditional squat jump in humans by engaging major leg muscles, including the 
quadriceps and gastrocnemii, to produce full flexion and extension of the hind limbs in 
response to the light stimulus.  In the final two OC sessions, rats wore unweighted 
Velcro
®
 vests, fitted over the scapulae, while completing the aforementioned movement.  
Once operant conditioned, rats were able to complete the exercise with minimal or no 
requirement for shock. 
After training, animals began an eight day voluntary resistance exercise program 
which consisted of four sessions (RE1-RE4), the first three separated by 48 hours each 
and the final session 72 hours after the third (Figure 2).  Five sets were completed during 
each of the four sessions, with gradually increasing loads and repetitions (reps) 
throughout each session and from day to day.  RE1 consisted of 30 to 230 grams 
progressively added to vests over a total of 50 reps, RE2 of 80 to 230 grams over 68 
reps, RE3 of 80 to 230 grams over 84 reps, and RE4 of 80 to 280 grams over 92 reps.  
Thus, excluding body mass, the total cumulative weights lifted increased from 5,500 
grams during RE1 to 15,460 grams during RE4.  Animals were given two seconds rest 
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between each repetition and two minutes rest between each set.  Rats assigned to 
sedentary conditions maintained normal cage activity for the duration of the experiment, 
however, they received the average number of shocks administered to exercised animals 
in an effort to minimize potential for confounding effects of negative reinforcement on 
skeletal muscle metabolism.  The final exercise bout was completed 16 hours preceding 
euthanasia.  
 
 
 
Figure 2.  Study design illustration.  Following one week of acclimation, animals in exercising 
groups were operant conditioned to perform a squat-like motion while suited with a Velcro
®
 vest 
adaptable for gradual increases in weights.  With little negative reinforcement, all trained rats 
completed a resistance exercise (RE) program consisting of four progressive sessions separated 
by either 48 or 72 hours (RE1-RE3 and RE3-RE4, respectively).  The final bout of exercise 
(RE4) ended 16 hours prior to euthanasia (EUTH).  Prior investigators in our lab assessed 
cumulative muscle protein synthesis (FSR) using deuterium oxide (
2
H2O) methodologies (29, 
53), wherein 24 hours prior to EUTH, all animals received an intraperitoneal (IP) bolus injection 
of 99.9% 
2
H2O and freely accessible 4% 
2
H2O drinking water.  DXA, dual-energy x-ray 
absorptiometry. Figure adapted with permission from Nilsson et al. (53). 
 
 
Tissue collection.  While free access to drinking water remained, food was 
discontinued four hours prior to tissue harvest.  As with previous research (18), all 
tissues were collected 16 hours following the last exercise session.  At that time, rats 
were anaesthetized with an IP injection of ketamine hydrochloride (Ketaset; 37.5 mg/kg 
DXA 
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BW) and medetomidine (Domitor; 0.25 mg/kg BW) then 2 ml of whole blood was 
exsanguinated via cardiac puncture.  The gastrocnemii were subsequently excised, and 
euthanasia with pentobarbital sodium followed.  Fat, blood, and connective tissues were 
removed before muscles were snap-frozen in liquid nitrogen, pulverized, and then stored 
at -80°C until used for the present study.  
Isolation of protein and western blot analysis.  All muscle tissue analyses in the 
current study were done using mixed gastrocnemius.  Western blot analyses were 
performed as previously described (16) with slight modification.  Briefly, pulverized 
muscle (~60 mg) was homogenized in 360 µl Norris buffer [25 mM Hepes, 5 mM β-
glycerophosphate, 200 µM ATP, 25 mM Benzamidine, 2 mM PMSF, 4 mM EDTA, 10 
mM MgCl2, 100 mM NF, 10 mM Na3VO4, Sigma protease inhibitor cocktail P8340 
(Sigma-Aldrich, St. Louis, MO), pH 7.4] and 40 µl of 10% TritonX100, placed on ice 
for one hour, then centrifuged at 14,000 revolutions per minute for 30 minutes at 4°C to 
separate the myofibrillar-rich (pellet) and cytosolic protein fractions.  The supernatant 
was decanted into new vials and the protein concentration was determined using 
bicinchoninic acid (BCA) assay, as described by Smith et al. (68).  Based on BCA assay 
results, samples were stored in 16 µl aliquots at -80°C until fully prepared for sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).   
Sample aliquots were thawed on ice, then cytosolic proteins were denatured by 
the addition of 4 µl of 4X Laemmli buffer (250 mM Tris base, 8% SDS, 40% Glycerol, 
0.004% bromophenol blue, 400 mM dithiothreitol [DTT]) followed by 10 minutes of 
heating at 100°C.  75 µg of cytosolic protein from each sample was loaded onto 10% 
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polyacrylamide gels (10 cm x 10 cm x 1.6 mm; 37.5:1 acrylamide: bisacrylamide) then 
separated by electrophoresis in standard electrode buffer (25 mM tris base, 19.2 mM 
Glycine, 0.1% SDS, pH 8.3) for approximately 1.5 hours at 40 mA (Owl™ P8DS 
System, Thermo Scientific, Rochester, NY).  Experimental groups were equally 
represented on all gels in an effort to minimize possible confounding effects of gel 
composition and electrophoresis condition on study outcomes.   
In preparation for semi-dry transfer, each gel was removed from SDS-PAGE set-
up and placed in Otter transfer buffer (49.6 mM Tris base, 384 mM glycine, 20% 
methanol [v/v], and 0.01% SDS [w/v]) for 10-15 minutes for equilibration following 
electrophoresis.  Additionally, two stacks of five filter papers (Munktell Filter Paper 
[Grade 1F], Sweden) were soaked for 10 minutes in Otter buffer, and one polyvinylidene 
fluoride (PVDF) membrane (Immobilon
®
-FL Transfer Membrane, 0.45 µm pore size, 
Millipore Corporation, Bedford, MA) was prepared according to manufacturer 
instructions.  Briefly, PVDF membrane was immersed in 100% methanol for 15 seconds, 
and then equilibrated for at least 5 minutes in transfer buffer before assembling the 
transfer stack.  All filter papers and transfer membranes were carefully cut so that when 
stacked, edges were uniform with those of the gel.  Assembly of the stack from cathode 
to anode plates of the transfer box (Owl™ HEP-1 Semi Dry Electroblotting System, 
Thermo Scientific) was as follows: 5 filter papers, gel, PVDF membrane, 5 filter papers.  
To ensure an even transfer, air bubbles were removed by carefully (to avoid disturbing 
the gel and membrane) rolling a glass culture tube over the stack.  Proteins were then 
transferred to the PVDF membrane at 300 mA for 40 minutes.  Consistency of loading 
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and efficiency of transfer were verified with reversible Ponceau S (0.1% Ponceau S 
[w/v], 5% acetic acid [v/v]) staining of each membrane and Coomassie blue (50% 
trichloroacetic acid [w/v], 0.1% Coomassie Brilliant Blue [w/v]) staining followed by 
destaining (50% methanol [v/v], 10% acetic acid [v/v]) of each gel.  
Following effective transfer of proteins from gel to membrane, each membrane 
was incubated for 1 hour in blocking buffer (95% 1X Tris-buffered saline [TBS], 5% dry 
milk [w/v]), and then incubated overnight at 4°C with gentle agitation in a heat-sealed 
plastic bag containing 1:1000 primary antibody: blocking buffer.  For this study, primary 
antibodies used were 13 kDa Rbx1 (#4397, Cell Signaling Technology, Inc., Danvers, 
MA) and 62 kDa β-TrCP (#4394, Cell Signaling Technology, Inc.).  A 3 x 5 minute 
serial wash step using 1X TBS followed, and then each membrane was incubated in 
1:2000 anti-rabbit IgG, horseradish peroxidase-linked secondary antibody (Cell 
Signaling Technology, Inc.): blocking buffer solution for 1 hour at room temperature 
with gentle agitation.  Following a repeated serial 1X TBS wash, each membrane was 
incubated for 5 minutes in 10 ml of enhanced chemiluminescent substrate (ECL) (equal 
parts SuperSignal
®
 West Pico Stable Peroxide Solution and SuperSignal
®
 West Pico 
Luminol Enhancer Solution) (Thermo Scientific, Rockford, IL), then protein bands were 
developed with a CCD camera mounted in a FluorChem™ SP imaging system (Alpha 
Innotech, San Leandro, CA).  Optical density was determined using AlphaEase FC 
software (Alpha Innotech), which was set to automatically subtract non-specific binding 
from densitometry values.  Density values were normalized between membranes and 
expressed as arbitrary units (AU).  
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Quantitative real-time polymerase chain reaction.  Polymerase chain reaction 
(PCR) analyses were performed at the University of Arkansas in collaboration with Dr. 
Nicholas P. Greene, PhD, a former doctoral student of Texas A&M University who has 
been involved with this project from its inception.  RNA was extracted with TRIzol
®
 
reagent (Life Technologies, Grand Island, NY) as suggested by the manufacturer.  Total 
RNA was isolated, DNase treated, and concentration and purity were determined by 
fluorometry using the Qubit
®
 2.0 protocol (Life Technologies).  Complementary DNA 
(cDNA) was reverse transcribed from 1μg of total RNA using Quanta qScript™ cDNA 
Supermix (Quanta BioSciences, Inc., Gaithersburg, MD).  Real-time PCR was 
performed using the StepOne™ Real-Time PCR system (Applied Biosystems®, Life 
Technologies) and results were analyzed using StepOne™ Software.  cDNA was 
amplified to 25μg containing appropriate primer pairs and TaqMan® Universal 
Mastermix (Applied Biosystems
®
, Life Technologies).  Samples were incubated at 50°C 
for 4 minutes, followed by 40 cycles of denaturation, annealing, and extension at 95°C, 
60°C, and 60°C, respectively.  TaqMan
®
 fluorescence was measured at the end of the 
extension step for each cycle.  Fluorescence labeled probes for DEPTOR, β-TrCP, Rbx1 
(FAM dyes), and 18S (VIC dye) were purchased from Applied Biosystems and were 
quantified with TaqMan
®
 Universal Mastermix.  Cycle Threshold (Ct) was determined 
and the Δ Ct value was calculated as the difference between Ct value and 18S Ct value.  
Final quantification of gene expression was calculated using the Δ Δ Ct method.  
Relative quantification was calculated as 2
-
 
Δ Δ Ct.  Data are presented as fold change of 
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gene expression relative to 18S ribosomal mRNA.  Melt curve analysis was performed at 
the end of each PCR run to verify that no dimers were formed.   
Statistical analyses.  The effects of phenotype (fatty vs. lean) and physical 
activity (sedentary vs. resistance exercised) on expression of Rbx1 and β-TrCP were 
evaluated using 2x2 ANOVA (SigmaStat 3.5, Systat Software, Inc., San Jose, CA).  
When significant F-ratios were observed, Fisher’s LSD post hoc analyses were 
performed to detect differences among group means.  Additionally, a priori 
consideration was given for sedentary cohorts between phenotypes (FS vs. LS), as well 
as for exercise within phenotypes (LE vs. LS, FE vs. FS), thus t-tests were performed 
when appropriate.  The level of significance was set at α=0.05 for all analyses.  All data 
are presented as group mean ± standard error of the mean (SEM).  
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RESULTS 
 
DEPTOR protein content is reduced with acute resistance exercise in lean 
Zucker rats.  Our group has previously reported than DEPTOR protein levels were 
reduced in lean exercised animals relative to their sedentary counterparts (LE vs. LS, 
p=0.025) (52).  Additionally, Nilsson et al. (52) reported no difference in DEPTOR 
protein levels of obese rats following acute resistance exercise, and that DEPTOR 
content in obese animals was similar to those of the lean exercised rats (Figure 3). 
 
 
 
Figure 3.  DEPTOR protein content.  LS, lean sedentary (n=8); LE, lean exercised (n=8); FS, 
fatty sedentary (n=6); FE, fatty exercised (n=8).  Data are expressed in arbitrary units of 
densitometry (AU) as group mean ± SEM.  Groups with the same letter are not significantly 
different (p>0.05).  Figure adapted from Nilsson et al. (52) and used under permission of Fair 
Use (USC Title 17 SCC 107). 
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DEPTOR mRNA is reduced and unresponsive to acute resistance exercise in 
obese Zucker rats.  A main effect of exercise was observed for DEPTOR mRNA in 
which the exercised animals expressed, on average, 30% less DEPTOR than sedentary 
animals.  There was also a main effect of phenotype in which DEPTOR mRNA was 
38% lower in obese compared to lean animals, on average (Figure 4).  Further analysis 
revealed obese sedentary rats (FS) exhibited 44% lower levels of DEPTOR mRNA 
compared to their lean littermates (LS) (p<0.001).  With exercise, levels of DEPTOR 
mRNA for lean rats (LE) were 37% lower (p<0.001) than those of their sedentary 
littermates (LS).  By contrast, obese exercised rats were not responsive (FE vs. FS, 
p=0.221) to exercise (Figure 4). 
 
 
 
Figure 4.  Fold change of DEPTOR gene expression.  LS, lean sedentary (n=6); LE, lean 
exercised (n=6); FS, fatty sedentary (n=6); FE, fatty exercised (n=6).  Data are presented as 
group mean ± SEM.  
‡
main effect of exercise (p<0.001); 
†
main effect of phenotype (p<0.001); 
*different from LS (p<0.05). 
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β-TrCP protein content is elevated in gastrocnemius muscle of obese Zucker rats 
and is unaffected by acute resistance exercise, regardless of phenotype.  There was a 
main effect of phenotype on β-TrCP protein content in which the level of β-TrCP protein 
in obese animals was 41% greater (p=0.024) than that of lean animals (Figure 5).  
However, β-TrCP protein content was not affected by acute resistance exercise.   
 
 
 
Figure 5.  β-TrCP protein content.  LS, lean sedentary (n=8); LE, lean exercised (n=7); FS, 
fatty sedentary (n=4); FE, fatty exercised (n=8).  Data are expressed as arbitrary units of 
densitometry (AU) as group mean ± SEM.  
†
main effect of phenotype (p<0.05). 
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β-TrCP gene expression is elevated with exercise in obese Zucker rats.  Results 
of a priori t-tests indicated no statistically significant differences between animals in 
sedentary groups (p=0.087), but greater expression of β-TrCP mRNA was observed in 
obese exercised rats compared to their sedentary counterparts (p=0.044).  Two-way 
ANOVA revealed no significant differences (p=0.062 for interaction between exercise 
and phenotype) (Figure 6).   
 
 
 
Figure 6.  Fold change of β-TrCP gene expression.  LS, lean sedentary (n=8); LE, lean 
exercised (n=6); FS, fatty sedentary (n=4); FE, fatty exercised (n=7).  Values are group mean ± 
SEM.  
ψ
different from FS (p<0.05). 
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Rbx1 protein content is reduced in gastrocnemius muscle of lean, but not obese 
Zucker rats following acute resistance exercise.  A main effect of acute resistance 
exercise was detected in which animals in exercised groups, on average, exhibited 30% 
lower Rbx1 protein levels (p=0.036) than those in sedentary groups, regardless of 
phenotype (Figure 7).  Further analysis revealed 49% lower levels of Rbx1 protein 
(p=0.012) in lean exercised (LE) animals only (Figure 7).  There were no differences in 
Rbx1 protein levels within the obese groups (FS vs. FE, p=0.673).  
 
 
 
Figure 7.  Rbx1 protein content.  LS, lean sedentary (n=8); LE, lean exercised (n=6); FS, fatty 
sedentary (n=6); FE, fatty exercised (n=8).  Data are expressed in arbitrary units of densitometry 
(AU) as group mean ± SEM.  
‡
main effect of exercise (p<0.05); *different from LS (p<0.05). 
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Rbx1 mRNA content is elevated with resistance exercise.  There was an observed 
main effect of exercise, in which animals in resistance exercised groups expressed 47% 
greater (p=0.032) Rbx1 mRNA content than those in sedentary groups (Figure 8).  
However, statistical relevance was not achieved within either the lean (p=0.253) or 
obese (p=0.057) phenotypes. 
 
 
 
Figure 8.  Fold change of Rbx1 gene expression.  LS, lean sedentary (n=6); LE, lean exercised 
(n=8); FS, fatty sedentary (n=4); FE, fatty exercised (n=6).  Values are group mean ± SEM.  
‡
main effect of exercise (p<0.05). 
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DISCUSSION AND CONCLUSIONS 
 
Our group (52) recently reported suppressed DEPTOR expression in obese 
Zucker rats.  Using the same animals and tissues to expand on that work, the primary 
goal of this investigation was to determine whether the observed DEPTOR levels are 
coordinated with levels of Rbx1 and β-TrCP, integral members of the SCF-type 
ubiquitin ligase complex which targets DEPTOR for degradation, in gastrocnemius 
muscle of rats with or without type 2 diabetes, with or without an acute resistance 
exercise intervention.  Altered levels of the DEPTOR regulatory proteins β-TrCP and 
Rbx1 have been observed and are associated with poor prognosis in numerous cancers 
(26, 27, 72, 75); however, to our knowledge these proteins have not been assessed in 
skeletal muscle, let alone an insulin-resistant model.  Thus, our study is the first to 
demonstrate that expression of β-TrCP protein in skeletal muscle is markedly elevated in 
the obese Zucker rat as compared to its lean littermate.  Furthermore, while it appears 
that the Rbx1 response to resistance exercise is reduced expression in lean animals, 
protein content of Rbx1 in the obese animal is rescued following exercise. 
Compared to lean animals, obese Zucker rats have markedly reduced levels of 
DEPTOR protein (52).  Given that DEPTOR is an inhibitor of mTOR, and mTOR is 
integral in promoting protein synthesis, in part through activation of S6K1, it is not 
surprising that the observed decrements in DEPTOR protein seem to correspond with 
elevated rates of protein synthesis in the obese Zucker rat (52, 53).  Supporting that 
notion are findings of a 2011 study from Kazi et al. (42) which demonstrated that 
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DEPTOR knockdown in C2C12 myoblasts, achieved via short hairpin (sh) RNA specific 
for the DEPTOR mRNA sequence, resulted in increased rates of protein synthesis 
attributed to mTOR activation of S6K1 and 4E-BP1.  Further, these authors conducted 
DEPTOR knockdown experiments in vivo using a mouse hind limb immobilization 
model, and found that muscle atrophy was prevented with knockdown in the 
immobilized limb (42).  Interestingly, gastrocnemius muscle mass independent of 
immobilization was unaffected by DEPTOR knockdown alone, suggesting that other 
contributors in the anabolic process are necessary to promote growth in skeletal muscle.  
Consistent with Kazi and colleagues (42), our work demonstrated that suppressed 
DEPTOR levels, elevated rates of muscle protein synthesis, and hyperactivation of 
mTOR and S6K1 in the obese Zucker rat were not associated with gains in muscle mass 
(52, 53).  Together, it appears that DEPTOR regulation is an important contributor to the 
preservation of muscle mass under atrophying conditions, albeit unsuccessfully with 
respect to the obese Zucker rat (52). 
The present study expands on previous work (52, 53) by assessing upstream and 
downstream contributors to DEPTOR expression as possible indicators for the altered 
content in obese Zucker rats.  Results from our work demonstrate that DEPTOR mRNA 
content (Figure 4) was remarkably consistent with DEPTOR protein content (Figure 3), 
with obese animals expressing less DEPTOR than their lean counterparts, suggesting 
that the elevated anabolic response in obese animals may, in part, be due to a diminished 
message ‘availability’ for the expression of DEPTOR protein.  Thus, a limited capacity 
for mRNA translation of DEPTOR, coupled with hyperinsulinemia accompanying 
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metabolic syndrome to augment mTOR activation, may serve to perpetuate the anabolic 
signal to offset the diminishing muscle mass in these animals.   
Furthermore, while mRNA content of DEPTOR was not affected by exercise in 
the obese animals, it was significantly reduced in lean animals and is consistent with the 
reduced DEPTOR protein levels following resistance exercise in lean Zucker rats (52).  
Our group (52) was the first to link DEPTOR as a potential regulator of the anabolic 
response to exercise in skeletal muscle, and it appears, in part, that alterations of 
DEPTOR content are via modifications to the availability of DEPTOR mRNA.  To that 
end, Peterson et al. (58) reported a downregulation of DEPTOR protein following 
activation of mTOR in HeLa cells as well as a downregulation of DEPTOR protein in 
cancer cell lines with ‘constitutive’ mTOR signaling.  Those authors (58) also 
demonstrated that reducing mTORC1 activity via shRNA specific for raptor resulted in 
increased DEPTOR protein and mRNA levels in HeLa cells, which is consistent with 
what our group (52) has observed using the phosphorylation of S6K1 (at threonine 389) 
as a surrogate marker of mTORC1 activity.  Nonetheless, more work is warranted as to 
how exercise or obesity alters mRNA content. 
The aberrant response to exercise in animals with insulin resistance has been 
previously documented by our lab group (31, 52, 53).  While it appears that altered 
mRNA content with obesity or exercise has a role in DEPTOR synthesis, the present 
investigation also explored the possibility that the dysregulation of anabolic processes in 
obese Zucker rats was due to altered degradation of the DEPTOR protein.  Specifically, 
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we focused on β-TrCP and Rbx1, key regulatory proteins of the SCFβ-TrCP complex 
which is a primary pathway used for the degradation of DEPTOR protein (15, 28, 80).  
β-TrCP is overexpressed in many cancers and seems to act as an oncogene, 
promoting tumor growth and survival (27).  Here we demonstrate that obese Zucker rats 
have elevated levels of β-TrCP protein in skeletal muscle in the basal state when 
compared to lean littermates (Figure 5).  However, it should also be noted that the 
elevation in protein content does not appear to be a result of altered mRNA content 
independent of exercise (Figure 6).  Additionally, β-TrCP protein content was unaffected 
by exercise (Figure 5), although β-TrCP mRNA content was greater in the obese 
following resistance exercise when compared to their sedentary littermates (Figure 6).  It 
is unclear as to why obese but not lean animals would have elevated mRNA content 
following exercise, but the lack of a response in lean animals is consistent with Zanchi 
and colleagues (78), who detected no change in mRNA content of β-TrCP in healthy rat 
plantaris after a 12 week resistance exercise training program.  Nonetheless, heightened 
levels of this important regulatory protein may be contributing to the observed reduction 
in DEPTOR protein content and the resultant chronic activation of S6K1 by mTOR, thus 
promoting feedback inhibition of IRS1 and exacerbating insulin resistance.  This 
obesity/metabolic syndrome-specific response warrants further investigation.  Frescas 
and Pagano (26) have suggested that the development of small molecule inhibitors of 
SCF ligases that target F-box proteins, especially β-TrCP, is essential for the future of 
cancer therapy.  If β-TrCP inhibition allows for the return of normal mTOR signaling 
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and maintenance by DEPTOR, perhaps controlled anabolic processes and insulin 
sensitivity could be restored in individuals with type 2 diabetes. 
Another important regulator of the SCF
β-TrCP
 complex, Rbx1, is an ubiquitin 
ligase that is bound to the scaffolding component (CUL1) of this important degradative 
machinery.  Thus, the regulation of this protein may have important implications for the 
SCF
β-TrCP
-dependent degradation of DEPTOR.  Several reports have indicated that 
independent regulation of this protein has strong implications on the progression of 
cancers (72, 75, 77).  Aside from cancer studies and independent of the SCF
β-TrCP
 
complex, Rbx1 has been purported to regulate the ubiquitination and degradation of 
S6K1 (57), a protein that promotes mRNA translation following phosphorylation by 
mTORC1 (82).  Panasyuk and colleagues (57) demonstrated that overexpression of 
Rbx1 led to increased S6K1 ubiquitination, while downregulation of Rbx1 promoted 
stabilization of S6K1 protein in human embryonic kidney (HEK) 293 cells.  Although 
Rbx1 protein levels were not different between lean and obese sedentary rats in the 
present study, our findings demonstrate a reduction in Rbx1 protein content following 
acute resistance exercise in lean animals (Figure 7), supporting the notion that reduced 
Rbx1 promotes S6K1 stability, which likely contributes to the elevated rates of protein 
synthesis observed in healthy skeletal muscle in response to an anabolic stimulus (52, 
53).  This reduction of Rbx1 protein levels cannot, however, be explained by a reduction 
in Rbx1 mRNA levels, as those were no different in lean animals following exercise 
(Figure 8), suggesting that enhanced degradation of the protein is the cause of the 
observed decrement.  Alternatively, the obese animals seemed to maintain Rbx1 protein 
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levels in the face of resistance exercise (Figure 7).  On average, animals that underwent 
resistance exercise had higher levels of Rbx1 mRNA (Figure 8), but that main effect of 
exercise was not sufficient to maintain Rbx1 protein levels in the lean animals (Figure 
7).  Of particular interest is that Rbx1 protein content was seemingly ‘rescued’ in the 
obese exercised animals (Figure 7), and although the mechanism behind this response is 
unclear, it appears to be a compensatory mechanism attempting to even further reduce 
the already low DEPTOR protein (Figure 3) and diminished mRNA content (Figure 4) in 
an unsuccessful effort to augment an anabolic response in muscle after exercise in these 
sarcopenic animals.  More work is necessary to resolve this speculation.  Furthermore, it 
should be noted that the maintenance of Rbx1 in obese animals was not accompanied by 
reduced total S6K1 protein content (52), which is consistent with the notion that skeletal 
muscle of obese Zucker rats is ‘desensitized’ to the anabolic effects of resistance 
exercise (31, 52, 53).   
Recent evidence from our group (52) indicates that the obese Zucker rat 
experiences a chronic activation of mTOR and S6K1 proteins, suggesting that Rbx1 
activity in obese cohorts is centered on the maintained suppression of DEPTOR in these 
animals.  The heightened FSR in the obese Zucker rat, coupled with an inability to 
augment protein synthesis following exercise (52, 53), may imply that these animals 
may be “locked” in an anabolic state, suggesting marked differences in proteolytic 
mechanisms in obese and lean animals.  In support of that speculation, we demonstrate 
here that the obese rats continue to express Rbx1 following resistance exercise, and this 
is perhaps caused by, and likely contributes to, anabolic dysregulation of skeletal muscle 
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with diabetes.  Future work should focus on the implications of Rbx1 expression as it 
relates to overall degradative processes in the cell, as well as how conditions of obesity 
and/or diabetes impact that regulation.   
In summary, the present investigation is the first to examine the DEPTOR 
regulatory proteins β-TrCP and Rbx1 in skeletal muscle of lean and obese Zucker rats.  
We have previously observed that obese Zucker rats function at elevated rates of 
anabolism when compared to lean littermates, and thus appear unresponsive to exercises 
that are known to stimulate anabolism (52, 53).  Here, we demonstrate that the 
heightened anabolic function in obese rats may be, in part, due to increased protein 
levels of β-TrCP, which may contribute to suppressed DEPTOR levels, resulting in 
uncontrolled mTOR activity in these animals.  Furthermore, the findings herein suggest 
that the β-TrCP/DEPTOR interaction may be a key culprit for the reported resistance to 
anabolic stimuli in diabetic skeletal muscle.  Results from this study may be of clinical 
importance.  As obesity and diabetes continue to increase in prevalence throughout the 
world, it is important to consider novel therapeutic targets for these diseased states.   
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